Alprostadil Injection Recalled Due to Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Alprostadil 40 mcg/ml Injection due to FDA inspection findings of GMP violations that may impact sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies GMP violations impacting sterility, which is a significant safety risk for an injectable drug. Per the rubric, FDA Class II recalls with significant injury/property-damage reports or structural defects are Severe; while no specific injuries are reported, the risk of sterility failure in an injectable is a significant hazard warranting a score of 4.
Plain-English summary
The Compounding Pharmacy of America is recalling Alprostadil 40 mcg/ml Injection, Sterile, Keep Frozen. The recall involves 76 mL total of the product distributed nationwide between November 2014 and May 2015. Specific lot codes and expiration dates are listed in the official recall documentation.
The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility. This lack of assurance of sterility poses a risk to patients using the medication.
Healthcare providers and patients should stop using the recalled product and contact the recalling firm or their healthcare provider for further instructions. The FDA classifies this as a Class II recall.
The recalled product
- Product
- Alprostadil 40 mcg/ml Injection, Sterile, Keep Frozen, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- All lots distributed between November 2014 and May 2015
- 01082015@34
- 7/7/2015
- 12162014@46
- 6/14/2015
- 02032015@98
- 8/2/2015
- 02112015@79
- 8/10/2015
- 02192015@15
- 8/18/2015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMontana Compounding Pharmacy Recalls Alprostadil Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-06-17
- SevereUS Compounding Recalls Alprostadil Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-25
- HighAlprostadil Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2021-11-17
- SevereAlprostadil Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereAlprostadil Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2021-11-17
- SevereAlprostadil 45mcg/mL Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2021-11-17